Chemiluminescence Immunoassay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Chemiluminescence Immunoassay Market is projected to expand from USD 12.63 Billion in 2025 to USD 16.94 Billion by 2031, achieving a compound annual growth rate of 5.02%. Chemiluminescence Immunoassay (CLIA) serves as a vital diagnostic technique that utilizes chemical reactions to emit light, allowing for the precise quantification of antigens and antibodies in clinical samples. This market growth is fundamentally propelled by the rising global prevalence of chronic and infectious diseases, which drives the need for accurate, high-throughput testing in laboratories. The scale of this demand is highlighted by the MedTech Europe 2024 estimate, which valued the European medical technology market at approximately €170 billion, with in vitro diagnostics representing the largest segment.

However, the market's expansion faces significant hurdles due to the substantial capital investment necessary for automated analyzer platforms. The high acquisition costs of these instruments, along with ongoing expenses for reagents and the need for specialized personnel, create a formidable financial barrier for smaller healthcare facilities and laboratories in resource-limited areas. Consequently, these economic constraints act as a primary impediment, potentially slowing the widespread adoption of this advanced diagnostic technology.

Market Drivers

The increasing global burden of chronic and infectious diseases serves as a primary catalyst for the Global Chemiluminescence Immunoassay Market. Clinical laboratories increasingly rely on CLIA due to its superior sensitivity and broad dynamic range compared to traditional methods. In oncology, precise biomarker detection is essential for early diagnosis; the American Cancer Society's "Cancer Facts & Figures 2025" projects 2,041,910 new cancer cases in the United States in 2025, generating immense demand for immunoassay testing. Similarly, high-sensitivity diagnostic tools are crucial for managing infectious diseases, where early detection is key to improving patient outcomes, further solidifying the technology's role in healthcare.

Simultaneously, technological progress in automated, high-throughput CLIA platforms is accelerating market growth by addressing operational challenges in modern laboratories. Diagnostic centers are shifting from manual ELISA methods to fully automated systems to handle rising testing volumes with faster turnaround times and reduced errors. This trend is evident in industry financials; the Roche Annual Report 2024 noted Diagnostics Division sales of CHF 14.3 billion, driven by immunodiagnostic demand. Furthermore, Abbott's "Fourth Quarter and Full-Year 2024 Results" from January 2025 showed a 4.3 percent rise in global Diagnostics sales excluding COVID-19, highlighting the sustained uptake of core diagnostic technologies.

Market Challenges

The significant capital required for automated chemiluminescence immunoassay (CLIA) analyzers acts as a major restraint on market growth. Smaller laboratories and healthcare facilities in resource-limited settings often lack the funds to cover the high upfront acquisition costs of these sophisticated instruments. Furthermore, recurring operational expenses, such as proprietary reagents and specialized maintenance, place additional strain on limited budgets. Consequently, many institutions remain reliant on lower-cost methods like ELISA, which restricts the broader adoption of CLIA technology and directly hinders market expansion.

These financial constraints are clearly reflected in industry spending patterns, which reveal limited resources for diagnostic departments. According to MedTech Europe, expenditure on in vitro diagnostics accounted for approximately 0.6% of total healthcare spending in 2024. This statistic underscores the disproportionately low funding allocated to the diagnostics sector relative to overall healthcare expenditure. Such restricted financial allocation limits the purchasing power of laboratories, rendering the procurement of expensive automated CLIA platforms financially unviable for a significant portion of the potential customer base.

Market Trends

The increased application of novel biomarkers for early detection is fundamentally reshaping the market, prompting clinical laboratories to shift from routine screening to high-value specialty testing. This trend involves the rapid adoption of advanced chemiluminescence assays for complex conditions like autoimmunity, endocrinology, and latent infectious diseases, which offer superior specificity compared to traditional methods. Manufacturers are aggressively broadening their test menus to include these niche biomarkers, thereby securing higher reimbursement rates and clinical relevance. This strategy is reflected financially; DiaSorin's "FY 2024 Results" in March 2025 reported a 9% year-over-year increase in ex-COVID immunodiagnostic revenues, explicitly attributed to the expansion of its specialty test menu.

Simultaneously, the market is undergoing strategic consolidation through mergers and acquisitions aimed at enhancing operational efficiency and portfolio integration. Major diagnostic players are combining point-of-care capabilities with core laboratory infrastructure to build unified diagnostic ecosystems that address fragmented healthcare delivery. These mergers enable companies to realize significant cost synergies and streamline manufacturing to offset high capital equipment costs. The success of this focus on efficiency is visible in QuidelOrtho's "Second Quarter 2025 Results" from August 2025, which announced the realization of $100 million in annualized cost savings, validating the benefits of recent integration initiatives.

Key Players Profiled in the Chemiluminescence Immunoassay Market

• Abbott Laboratories Inc.
• Beckman Coulter, Inc.
• DiaSorin S.p.A
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• QuidelOrtho Corporation

Report Scope

In this report, the Global Chemiluminescence Immunoassay Market has been segmented into the following categories:

Chemiluminescence Immunoassay Market, by Product:

• Instruments
• Consumables
• Software & Services

Chemiluminescence Immunoassay Market, by Sample Type:

• Blood
• Urine
• Saliva
• Other

Chemiluminescence Immunoassay Market, by Application:

• Therapeutic Drug Monitoring
• Oncology
• Cardiology
• Endocrinology
• Infectious Disease
• Autoimmune Disease
• Other

Chemiluminescence Immunoassay Market, by End User:

• Hospitals
• Clinical Laboratories
• Pharmaceutical & Biotechnology Companies
• Other

Chemiluminescence Immunoassay Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemiluminescence Immunoassay Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.